Medium Versus High Initial Prednisone Dose for Remission Induction in Lupus Nephritis: A Propensity Score–Matched Analysis
- 4 March 2021
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 74 (9) , 1451-1458
Abstract
Objective: The existing guidelines for lupus nephritis (LN) recommend initial prednisone doses of 0.3–1.0 mg/kg/day. However, recent studies reported noninferior outcomes with lower doses. The aim of this study was to compare the complete renal response rates in LN patients treated with prednisone ≤30 mg/day or ≥40 mg/day.Methods: Patients with new‐onset LN and standard immunosuppressive treatment were followed for at least 12 months, divided into medium (≤30 mg/day) and high prednisone groups (≥40 mg/day) and matched (propensity score) based on the baseline differences. Complete renal response was defined as proteinuria P = 0.024) at 12 months. The difference in response rates was reproduced for several subgroups (concomitant immunosuppressive treatment, proliferative/nonproliferative LN). Complete remission rates were higher at 2 years (67.8% versus 39%; P = 0.002) and 3 years (64.9% versus 49.1%; P = 0.025) after LN diagnosis. Cumulative glucocorticoid dose was comparable at 2 and 3 years. Glucocorticoid‐related damage was accelerated in both groups for the same period.Conclusion: Higher initial prednisone doses (median 45 mg/day) achieved significantly better rates of complete renal response at 12 months in new‐onset LN. Cumulative glucocorticoid dose and damage accrual were not different at 2 and 3 years after LN. Damage was more prominent in the late phases of LN in both groups, underlining the importance of rapid tapering and the need to implement alternative strategies.Keywords
Funding Information
- CIHR
- Lupus Canada
This publication has 25 references indexed in Scilit:
- Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroidsAnnals of the Rheumatic Diseases, 2013
- American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritisArthritis Care & Research, 2012
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studiesPharmaceutical Statistics, 2011
- Cushing’s syndrome, glucocorticoids and the kidneyGeneral and Comparative Endocrinology, 2010
- Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus NephritisJournal of the American Society of Nephrology, 2009
- Value of a Complete or Partial Remission in Severe Lupus NephritisClinical Journal of the American Society of Nephrology, 2008
- Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus NephritisNew England Journal of Medicine, 2005
- Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamideArthritis & Rheumatism, 2002
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosusArthritis & Rheumatism, 1996